

1 Fe

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
Army 178

In Re Application Of: **Tsokos**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/772,704	February 5, 2004		30951		

Title: **Novel Method for the Treatment of Systemic Lupus Erythematosus**

Address to:
**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army 178

In Re Application: Tsokos

SEP 24 2004

Application No. 10/772,704	Filing Date February 5, 2004	Examiner	Customer No. 30951	Group Art Unit	Confirmation No.
-------------------------------	---------------------------------	----------	-----------------------	----------------	------------------

Title: Novel Method for the Treatment of Systemic Lupus Erythematosus

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" September 23, 2004.

(Date)

Signature of Person Mailing Correspondence

Caroline Nash

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Caroline Nash


Signature

Dated: September 23, 2004

Caroline Nash, Reg. No. 36,329

Customer No. 30951

CC:



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army 178

Application Number

0/772,704

Applicant(s)

Tsokos

Filing Date

February 5, 2004

Group Art Unit

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

		Tenbrock, " Antisense cyclic adenosine 5'-monoshosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus", Jour. of Immun. vol. 169, no. 8, 15 Oct. 2002, pages 4147-4152
		Database WPI, sect. Ch, Week 199929, Serwent Publications Ltd., London, GB; Class Bo4, AN 1999-340518, XPOO22904 & JP 11 123082 A, 11 May 1999, Abstract

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional)	Application Number	
		Army 178		10/772,704
		Applicant(s)		Group Art Unit
		Tsokos		
		Filing Date		
		February 5, 2004		

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
	Yoshimoto Keiko et al., "Antisense repression of TCR zeta chain alters cell proliferation and IL-2 production in Molt-4 cell line.", Arthritis and Rheumatism, vol. 42, no. 9, SUPPL., Sept. 1999, pages S95 XP008034010 &63rd annual scientific meeting of the American College of Rheumatology and the 34th annual scientific; Boston, Mass. , Nov. 13-17, 1999 Abstract 146				
	Solumou E E et al. "Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus." Journal of Immunology (Baltimore, MD 1950) 15 March 2001, vol. 166, no. 6., pages 4216				
	Liossis, et al. "Altered prtrtern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cell from patients with systemic lupus erythematosus..." Journal of Clinical Investigation, vol. 101, no. 7, 4/1/98, pages 1448-1457.				
	kammer et al., "Abnormal T lymphocyte signal transduction in systemic lymphocyte signal transduction in systemic lupus erythematosus." Cruuent Directoins In Autoimmunity. 2002, vol. 5, 2002, pages 131-150.				
	Herndon, et al., "Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity, Clinical Immunology (Orlando, FL) May 2002.				
	Database Biosis 'Online! Biosciences Information Service Philadelphia, PA US; May 2003 (2003-05), Tsokos et al, "Re2wiring the T-cell: Signaling defects and novel prospects for the treatment of SLE." Database accession No. PREV2003300292284. Abstract				
	Database medline Online, US National Library of Medicine, Bethesda, MD , July 2003, Nambiar Madhussodana, et al, "Reconstitution of Deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with syt=stemic lupus erythematosus." abstract &Arthritis and Rheumatism., Jul 2003, vol. 48, no. 7, July 2003, pges 1948-1955.				
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">EXAMINER</td> <td style="width: 50%;">DATE CONSIDERED</td> </tr> <tr> <td style="height: 40px;"></td> <td></td> </tr> </table>		EXAMINER	DATE CONSIDERED		
EXAMINER	DATE CONSIDERED				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.